Non-Hodgkin's lymphoma


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

Non-Hodgkin's lymphoma (NHL)

[- hoj′kənz]
solid tumors of peripheral lymphoid tissue classified by histological features and lymphocyte morphology. Distinguished from Hodgkin's lymphoma, a proliferation of Reed-Sternberg cells with accumulation of reactive peripheral blood cells. Non-Hodgkin's lymphoma prevalence peaks at 50 years of age and may be mild or aggressively malignant, depending upon cell category. Once called lymphosarcoma or sarcoma.
enlarge picture
Non-Hodgkin's lymphoma

non-Hodgkins' lymphoma

A lymphoid cancer that is not Hodgkins disease: NHL ALL, B cell lymphoma, Burkitt's lymphoma, diffuse cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, mycosis fungoides, post-transplantation lymphoproliferative disorder, small non-cleaved cell lymphoma, T-cell lymphoma Epidemiology Incidence ↑ 8.5/105 in 1973→15/105 in 1990 (21/105, in 2000, Canada ♂), ±53,900 new cases/yr, US in 2002; 60% of all lymphomas are NHLs, of which 55% are diffuse, 45% are nodular Risk factors AIDS, primary immunodeficiency, immunosuppression, transplants, exposure to pesticides, hair dyes, smoking, alcohol, in older ♀–linked to ↑ consumption of meat/animal fats– Management Chemotherapy, especially CHOP Complications Spinal cord compression occurs in up to 10%, which is often aggressive, and may respond to high-dose RT. See Lymphoma, REAL classification, Working Formulation.
Non-Hodgkin's lymphoma
Stage I CA present in only one lymph node area or in only one extranodal regional/organ
Stage II CA present in ≥ 2 lymph node areas on same side of diaphragm; CA present in only one extranodal area or organ outside the lymph nodes and in the lymph nodes around it. Other lymph node areas on the same side of the diaphragm may also have cancer
Stage III CA present in lymphoid tissue on both sides of the diaphragm; tumor may also have spread to an area or organ near the lymph node areas and/or to the spleen
Stage IV CA has spread to > one organ or organs outside lymphoid tissue; CA has spread to only one organ outside the lymph system, but lymph nodes distant from that organ are involved

Non-Hodgkin's lymphoma

Cancer that originates in the lymphatic system and typically spreads throughout the body.
References in periodicals archive ?
Usually ocular non-Hodgkin's lymphoma mainly involves the elderly.
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.
Non-hodgkin's Lymphoma Preclinical Research Pipeline Insights
Finally, she observes that although AIDS, organ transplantation, and certain rare genetic disorders appear to predispose individuals to developing non-Hodgkin's lymphomas, these risk factors "couldn't begin to explain the level of increased incidence that has occurred throughout the world.
These initial findings support that SAR3419 offers potential for the treatment of B-cell non-Hodgkin's lymphoma, including rituximab-refractory disease," commented John Lambert, PhD, Executive Vice President and Chief Scientific Officer, ImmunoGen.
During the 7-year study, 104 of the women developed non-Hodgkin's lymphoma.
The Company's other lead product is BiovaxID(TM), a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma.
In February, researchers reported that women who had relied on black hair dye for 20 years or longer ran a slightly increased risk of dying from certain blood-based cancers, such as non-Hodgkin's lymphoma (SN: 2/5/94, p.
Pharmacogenetic Test to Aid Physicians in Managing Therapy for Patients with Follicular non-Hodgkin's Lymphoma
For example, Thun and his colleagues found that, compared to women who didn't color their hair, women who used permanent black hair dye for 20 years or longer ran about a four times greater risk of dying from non-Hodgkin's lymphoma, a cancer of the lymph tissue, or multiple myeloma, a malignancy of the bone marrow cells that produce antibodies.
The trial will compare treatment with galiximab in combination with rituximab (RITUXAN([R])) to rituximab in combination with placebo in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed or failed to respond to initial therapy.